Status:
COMPLETED
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Schizophrenia
Eligibility:
All Genders
18-55 years
Phase:
PHASE3
Brief Summary
This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
Detailed Description
Schizophrenia is a devastating brain disorder. Most people with schizophrenia have difficulty filtering out unimportant auditory information. They have an inability to appropriately inhibit, or gate, ...
Eligibility Criteria
Inclusion
- Meets DSM-IV criteria for schizophrenia
- Stable, chronic schizophrenia
- Currently taking atypical medications
- Use of effective form of contraception throughout study
Exclusion
- History of any alcohol or drug abuse within 3 months of study start date
- Any other major neurological disorders
- History of or current head trauma
- Any medical conditions affecting the central nervous system
- Current epilepsy, asthma, migraine headache, previous myocardial infarction, stroke, diabetes, hypertension, narrow angle glaucoma, or neuromuscular illnesses
- Pregnant
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00149734
Start Date
January 1 2005
End Date
May 1 2010
Last Update
August 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Denver VAMC
Denver, Colorado, United States, 80220